Effects of Resveratrol Supplements on Vascular Health in Postmenopausal Women

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Cardiovascular Disease

In brief

The investigators hope to learn if resveratrol supplementation can be beneficial for the cardiovascular system. Seeing that resveratrol is rapidly metabolized, the investigators are interested in learning if a novel form of resveratrol, ResA, which is a mixture of resveratrol with amino acid, may have greater bioavailability and lead to greater improvement in vascular function, compared to standard resveratrol supplement.

Key facts

Study ID

NCT01564381

Run by

University of California, Davis

People needed

64

Starts

2012-03-01

Expected to finish

2015-03-01

Last updated by the study team

2017-07-14

Who can join

Age: 50 and older, up to 70. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• 50 to 70 years of age
• Lack of menses in the last year and FSH 23-116.3 mlU/mL
• Subject is willing and able to comply with the study protocols.
• Subject is willing to consume resveratrol supplements/placebo capsules on three separate occasions.
• BMI 18.5-34.9 kg/m2
• Weight ≥ 110 pounds
• LDL-C ≥ 130 mg/dL

You may not qualify if…

• BMI ≥ 35 kg/m2
• Self reported use of anticoagulation agents including NSAIDs
• Self reported use of oral cortisone or other immunosuppressive agents,
• Self reported underlying neoplasia or immunological disease
• Food faddists or those taking a non-traditional diet
• Self reported physical activity restricted or reduced due to chronic health conditions
• Self reported diabetes
• Blood pressure ≥ 140/90 mm Hg
• PFA-100 readings 10 % outside of normal reference range (normal reference range for ADP-Collagen: 71-118 sec; Epinephrine-Collagen: 94-193 sec).
• Self reported renal or liver disease
• Self reported heart disease, which includes cardiovascular events and stroke
• Self reported Cushing's syndrome
• Self reported chronic/routine high intensity exercise
• Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT
• Abnormal Liver, CBC or Chemistry panels (laboratory values outside the reference range) if determined to be clinically significant.
• Self reported cancer within past 5 years
• Self reported history of psychiatric disorders i.e. schizophrenia or bi-polar or depression treated with antidepressants within the last 1 year.
• Self reported use of MAOI inhibitor within the last 1 year (e.g. phenelzine (Nardil), tranylcypromine (Parnate), etc)
• Self reported malabsorption (e.g. difficulty digesting or absorbing nutrients from food,

Where it is running

• University of California, Davis - Ragle Human Nutrition Research Center — Davis, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.